Skip to main content
Clinical Trials/DRKS00028129
DRKS00028129Completed未知

Changes in neural processing and evaluation of negative facial expressions after administration of an open-label placebo - OLP and affective processing

niversität Graz0 sites109 target enrollmentStarted: February 18, 2022Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
109

Study Overview

Brief Summary

A recent event-related potential (ERP) study found that an open-label placebo (OLP) reduced emotional distress during the viewing of unpleasant scenes and the amplitude of the late positive potential (LPP). The present ERP experiment aimed at a conceptual replication of this finding and investigated OLP effects during affective face processing. The participants (109 females) were presented with images depicting angry and neutral facial expressions after the administration of a saline nasal spray. The spray was either introduced as a placebo that could help reduce the emotional reactions to viewing angry faces (OLP group) or to improve the electrophysiological recordings (Control group). The OLP was associated with reduced LPP amplitudes (1000–6000 ms) to anger expressions across a frontal cluster. Additionally, the OLP reduced LPP amplitudes (400–1000 ms) to both anger and neutral faces across a centroparietal cluster. Compared to the Control group, the OLP group reported less arousal when confronted with angry faces, and rated the anger expressions as less intense. This study demonstrates that an OLP can alter both subjective and neural responses to anger cues. Future research should directly compare OLP treatment with other strategies for emotion regulation (e.g., cognitive reappraisal) to demonstrate the specificity of this approach.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 40 Years (—)
Sex
Female

Inclusion Criteria

  • adult, female

Exclusion Criteria

  • self-reported mental disorders/ somatic ilness; psychotropic medication

Investigators

Sponsor
niversität Graz

Similar Trials